Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteIgE immunotherapy against cancerA phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupImmunotherapy for pediatric cancer.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISAComparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.Immunotherapy of neuroblastoma: present, past and future.Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.PPARgamma in Neuroblastoma.Disialoganglioside directed immunotherapy of neuroblastoma.Toxicity as a result of immunostimulation by biologics.Novel antibodies as anticancer agents.Novel delivery methods to achieve immunomodulation.Intratumoral immunocytokine treatment results in enhanced antitumor effects.Animal models for IgE-meditated cancer immunotherapyTargeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology GroupPhase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.Immune therapies for neuroblastoma.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Anti-GD2 antibody therapy for GD2-expressing tumors.New therapies in the treatment of melanoma.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Immunocytokines: a review of molecules in clinical development for cancer therapy.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linkerAnti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
P2860
Q28066935-593FE4EE-BA93-4D0E-AD0B-BD2479931B0CQ28081223-D4CACFF7-E24F-4DB9-9459-9FDBA7B61AF0Q33370628-7F739AF1-FECF-4E47-B8E2-A0FEBB50BEF4Q33924586-74FB2208-3C8B-4B14-95F9-35BEFF048A7CQ34186886-22DB6E30-AE31-455C-97D6-2C73DE9EA1ADQ34488726-70CC5862-8747-4175-BBE7-F12A31A5598CQ34548847-B7D292BC-839E-442D-A3FE-22E78264FC5DQ34683623-2ACB8A32-89A4-4454-ACBC-FC513689BE34Q34764827-C3F82F4E-3E74-4E83-9F33-A1437CF1DA74Q35077759-5151D02D-D02C-43C0-97BB-4ACA6257BC39Q35381031-E6B78FC4-AF8B-47CC-8E10-20EAC43C8687Q35587509-DFE548D8-D518-4C6C-A290-3F6B4D3963B8Q36179663-475FDC84-394E-4F94-A013-3F04F584F53EQ36412879-D2341FA1-62D6-4DCD-9BA2-DF94F4F71D89Q36453273-5E0E0283-D224-48A0-8E72-955BE0E7652FQ36459340-961F4F1C-B783-4FE9-AC8B-4677A7CCAF1EQ36678476-E8BDC5C9-5D3B-4A26-B32C-1599DDF3DE36Q36761416-2C6D05FB-FAA6-40D6-B616-3B9EEFB681DFQ36788414-736AA096-6577-40AF-82F6-864D5AC9B6D5Q36832141-33A0D589-B172-4211-A469-FAE2EE89438EQ36870418-A48B24C4-B696-4465-A8DD-5E415C1ECF53Q36953492-C03E00EF-B92D-465C-AE4B-02B8064942D9Q37031457-791C8660-2C1D-48FA-ADBE-D5A0BD88C5F2Q37035553-5342B290-194C-4EC6-8A73-D1AE5E15B799Q37038652-B85A118B-9F56-4DEE-B7FD-2089475E0624Q37059790-7568B378-971A-44EC-B5D3-57DE3B6059D2Q37103078-FD29C7A7-6FA2-4668-8DE0-2B3190307736Q37299181-9D08066B-366E-4682-A7A9-EF5623BD7AA0Q37431356-CCCD5C4F-9114-46C3-8BBB-0F650E27CE95Q37453905-7676A632-3138-450E-A648-C04D7D5B82FBQ37485709-3D5CA08A-5DEF-49A8-81B2-3216704FD977Q37624276-1D8D5902-5B16-4079-9A72-2C4DDC9EE7EEQ37637949-1B051188-7DD0-4FC2-AC71-0316EFDA85C6Q37702283-38FC009E-0A70-4E08-A65B-AB00F970F306Q38033197-3D1E60D6-D838-4D52-8A00-314C174F78D7Q38088357-702F8F31-EB3B-4581-A9FC-E17044391668Q38132742-D3B94C34-15D4-4F97-8DD3-77F9CA0BEED5Q38652655-5B66495E-AAD1-4EAA-8CB5-4D13D4E960C9Q38772382-E1B06AB4-7FA0-48CF-80D3-703B1A3355F5Q38916529-C1C5F5B5-F39F-45CE-82AD-7BDCD5D35932
P2860
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@ast
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@en
type
label
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@ast
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@en
prefLabel
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@ast
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@en
P2093
P2860
P356
P1476
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
@en
P2093
David M King
David Mahvi
Heidi Schalch
Jacquelyn A Hank
Jean Surfus
Jens Eickhoff
Joan H Schiller
Kari Kendra
KyungMann Kim
P2860
P304
P356
10.1200/JCO.2004.11.035
P407
P577
2004-10-13T00:00:00Z